Hudson Bay Capital Management LP Incyte Corp Transaction History

Hudson Bay Capital Management LP

$24.1 Billion
Q4 2024

A detailed history of Hudson Bay Capital Management LP transactions in Incyte Corp stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 100,000 shares of INCY stock, worth $7.21 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

100,000

Previous 221,574 54.87%

Holding current value

$7.21 Million

Previous $14.6 Million 52.85%

% of portfolio

0.03%

Previous 0.07%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$65.08 - $83.38 $10.7 Million - $13.7 Million	-164,065 Reduced 74.05%	57,509 $3.97 Million
Q3 2024 Nov 13, 2024	BUY	$57.33 - $68.61 $130,368 - $156,019	2,274 Added 1.04%	221,574 $14.6 Million
Q2 2024 Aug 14, 2024	SELL	$51.18 - $63.75 $4.15 Million - $5.17 Million	-81,133 Reduced 27.01%	219,300 $13.3 Million
Q1 2024 May 15, 2024	SELL	$56.55 - $66.59 $1.53 Million - $1.8 Million	-27,067 Reduced 8.26%	300,433 $17.1 Million
Q4 2023 Feb 14, 2024	SELL	$52.16 - $64.19 $9.61 Million - $11.8 Million	-184,285 Reduced 36.01%	327,500 $20.6 Million
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $9.14 Million - $10.4 Million	-158,215 Reduced 23.61%	511,785 $29.6 Million
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $31.1 Million - $38.5 Million	509,800 Added 318.23%	670,000 $41.7 Million
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $2.82 Million - $3.46 Million	40,200 Added 33.5%	160,200 $11.6 Million
Q4 2022 Feb 14, 2023	SELL	$67.18 - $84.11 $2.12 Million - $2.65 Million	-31,500 Reduced 20.79%	120,000 $9.64 Million
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $6.39 Million - $8 Million	96,500 Added 175.45%	151,500 $10.1 Million
Q2 2022 Aug 12, 2022	BUY	$66.18 - $83.18 $661,800 - $831,800	10,000 Added 22.22%	55,000 $4.18 Million
Q1 2022 May 16, 2022	SELL	$66.02 - $79.71 $3.63 Million - $4.38 Million	-55,000 Reduced 55.0%	45,000 $3.57 Million
Q4 2021 Feb 14, 2022	SELL	$63.34 - $74.11 $2.38 Million - $2.78 Million	-37,500 Reduced 27.27%	100,000 $7.34 Million
Q3 2021 Nov 15, 2021	BUY	$68.67 - $84.02 $5.32 Million - $6.51 Million	77,500 Added 129.17%	137,500 $9.46 Million
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $1.6 Million - $1.75 Million	20,000 Added 50.0%	60,000 $5.05 Million
Q1 2021 May 14, 2021	BUY	$76.02 - $100.5 $1.52 Million - $2.01 Million	20,000 Added 100.0%	40,000 $3.25 Million
Q4 2020 Feb 12, 2021	BUY	$80.74 - $97.7 $1.61 Million - $1.95 Million	20,000 New	20,000 $1.74 Million
Q2 2020 Aug 12, 2020	SELL	$74.18 - $108.93 $2.6 Million - $3.81 Million	-35,000 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$63.18 - $85.97 $947,700 - $1.29 Million	15,000 Added 75.0%	35,000 $2.56 Million
Q4 2019 Feb 12, 2020	SELL	$73.04 - $95.72 $1.83 Million - $2.39 Million	-25,000 Reduced 55.56%	20,000 $1.75 Million
Q3 2019 Nov 13, 2019	BUY	$72.82 - $86.52 $3.28 Million - $3.89 Million	45,000 New	45,000 $3.34 Million
Q1 2019 May 15, 2019	SELL	$63.56 - $88.17 $1.91 Million - $2.65 Million	-30,000 Closed	0 $0
Q4 2018 Feb 13, 2019	SELL	$58.5 - $69.94 $836,550 - $1 Million	-14,300 Reduced 32.28%	30,000 $1.91 Million
Q3 2018 Nov 14, 2018	BUY	$61.75 - $74.23 $265,525 - $319,189	4,300 Added 10.75%	44,300 $3.06 Million
Q2 2018 Aug 13, 2018	BUY	$60.85 - $83.98 $1.19 Million - $1.64 Million	19,526 Added 95.37%	40,000 $2.68 Million
Q1 2018 May 14, 2018	SELL	$83.06 - $100.98 $5.4 Million - $6.56 Million	-65,000 Reduced 76.05%	20,474 $1.71 Million
Q4 2017 Feb 12, 2018	BUY	$93.56 - $116.6 $2.81 Million - $3.5 Million	30,000 Added 54.08%	85,474 $8.1 Million
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $6.05 Million - $7.67 Million	55,474	55,474 $6.48 Million

Others Institutions Holding INCY

# of Institutions

706

Shares Held

189M

Call Options Held

909K

Put Options Held

489K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.

Account

Hudson Bay Capital Management LP Incyte Corp Transaction History